ACL Healius Bid Bordering on the Pathological
Even though the Covid testing boom is over, Australian Clinical Labs still wants to create the country’s largest pathology provider by taking over the number one tester, Healius.
Read MoreTag: HLS
HLS – Morgans rates the stock as Add
The target price falls to $4.30 from $5.15 and the Add rating is maintained.
Read MoreHLS – Macquarie rates the stock as Outperform
The Outperform rating and target price of $5.20 are retained.
Read MoreHLS – Macquarie rates the stock as Outperform
After allowing for earnings revisions and an updated Macquarie risk-free rate, the target falls to $5.20 from $5.40, while valuation appeal sees the Outperform rating kept.
Read MoreTuesday Trading Talk: UWL, HLS
Corporate action afoot for a couple of industrial companies, with telco Uniti the subject of a takeover at $4.50 per share and healthcare provider Healius announcing a $A100m buyback.
Read MoreHLS – Macquarie rates the stock as Outperform
The Outperform rating is retained and the target price increases to $5.40 from $5.30.
Read MoreHLS – Credit Suisse rates the stock as Outperform
Outperform retained. Target rises to $5.50 from $5.35.
Read MoreHLS – Credit Suisse rates the stock as Outperform
Outperform retained. Target is raised to $5.35 from $5.00.
Read MoreHLS – Macquarie rates the stock as Outperform
Outperform retained. Target rises to $4.85 from $4.70.
Read MoreHLS – Credit Suisse rates the stock as Outperform
The Australian government has announced an additional $1.1bn in funding for Australia’s health response to covid-19 and will extend pathology testing for a further nine months to December 31 2021. Credit Suisse’s Outperform retained. Target is $4.25.
Read MoreHealius Confirms Buyback After Completing Medical Centre Sale
Private healthcare group Healius has done what it was expected to do after selling off its GP business and revealed plans for a large share buyback.
Read MoreHLS – Credit Suisse rates the stock as Outperform
Healius has completed the sale of its Medical Centres business to BGH Capital, receiving $483m. Credit Suisse believes the company could return up to $200m to shareholders via a special dividend and increase the ordinary dividend payout ratio.
Read MoreHealius Health Offloads Medical Centres To Private Equity
Private healthcare company Healius has netted $483 million after completing the sale of its medical centres business to BGH Capital (which is bidding for Village Roadshow).
Read MoreHLS – Macquarie rates the stock as Outperform
Macquarie reviews the pathology margins, noting these have declined over time but expansion is now likely to FY23.
Read MoreHLS – Morgans rates the stock as Hold
Healius provided a trading update, expecting to report FY20 underlying earnings (EBIT) of $102m-$104m and underlying profit (NPAT) of $54m-56m. Morgans states that covid-19 impacts were seen across all segments, with Imaging and Day Hospitals/IVF faring the worst, while Pathology did better as covid-19 testing helped buffer declines across base testing.
Read MoreHLS – Credit Suisse rates the stock as Outperform
Credit Suisse analyses the opportunity for profitability to improve in pathology as the company sells its medical centre businesses.
Read MoreHLS – Macquarie rates the stock as Upgrade to Outperform from Neutral
Macquarie reviews the near-term growth assumptions and assumes a less substantial impact from the pandemic. The broker believes Healius is positively leveraged to improved activity levels heading into FY21.
Read MoreHLS – Credit Suisse rates the stock as Neutral
Healius has withdrawn FY20 guidance. The company is currently completing around 2500 tests for coronavirus per day but this is not enough to offset the volume drop from fewer GP attendances and the deferral of elective pathology & radiology work.
Read MoreNot So Fertile Ground For IVF Leader
The flagging housing market and sagging consumer sentiment ahead of the federal and NSW elections have affected the performance of an unlikely ASX-listed exponent – the assisted reproduction outfit Virtus Health (VRT, $3.98).
Read More
